Allergic conjunctivitis

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Retrieved on: 
Monday, December 18, 2023
People, Eye, Allergic conjunctivitis, Select, Anatomy, ATC, Safety, European Medicines Agency, Ageing, International, IGA, INN, Disease, Language, Overview, Dry, Patient, IIA, Thigh, Conjunctivitis, Marketing, EASI, Atopic dermatitis, Medical Subject Headings, Diagnosis, Red, Skin, Human, Inflammation, Instrumentation, Medicinal plants, Medical device, Copper, Vaccine, Medical imaging, Online shopping, Bookkeeping, Dermatitis, Medicine

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
FDA, Research, Growth, ASC, Axitinib, ASCRS, Food, Intraocular pressure, SOL, Medicare, Eye, Telecanthus, Abdominal ultrasonography, OHT, AMD, OAG, Overalls, CPT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inflammation, Patient, OPPS, Interest, Allergic conjunctivitis, Clinical trial, Marketing, Webcast, Barings LLC, Macular degeneration, Depreciation, Safety, SPA, Visual acuity, Trial of the century, Pain, Centers for Medicare & Medicaid Services, CMS, Pharmaceutical industry, Beauty salon, Fine chemical, Medical device, Birth control, Video game

BEDFORD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the third quarter ended September 30, 2023, and provided updates on its ophthalmology pipeline.

Key Points: 
  • “We made significant progress at Ocular Therapeutix in the third quarter,” said Antony Mattessich, President and CEO.
  • The Company also recorded gains and losses from debt extinguishment, net, of $14.2 million in the third quarter of 2023.
  • Non-cash charges for stock-based compensation and depreciation and amortization were $5.4 million in the third quarter of 2023 versus $4.7 million for the comparable quarter in 2022.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

Retrieved on: 
Tuesday, October 24, 2023
Surgery, Medical Supplies, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Optical, New Drug Application, Full, Shirin David, Vernal keratoconjunctivitis, Tobramycin, Acquisition, VKC, Keratitis, Allergic conjunctivitis, Risk, Marketing, Cornea, Conjunctivitis, Eye, AmerisourceBergen, NDA, McKesson Corporation, Pharmaceutical industry

NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal for treating fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.

Key Points: 
  • NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal for treating fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.
  • ZERVIATE® (cetirizine ophthalmic solution) 0.24%, a histamine-1 (H1) receptor antagonist indicated for treating ocular itching associated with allergic conjunctivitis.
  • Harrow announced its acquisition of the U.S. commercial rights of these products in July of 2023.
  • To date, Harrow has been receiving profit transfers on these products; however, with the transfer of the NDAs completed, Harrow has launched these products in the U.S. under the Harrow name.

Competitive Landscape in 2023 Conjunctivitis Treatment Market Features Key Players like Novartis, Allergan, and More - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 17, 2023
General Health, Pharmaceutical, Optical, Health, Alembic Pharmaceuticals, Subconjunctival bleeding, BMC, Allergy, Allergic conjunctivitis, Nature, Prevalence, Allergan, NCBI, COVID-19, Conjunctivitis, USD, Vernal keratoconjunctivitis, NicOx, Incidence, Eyelid, Novartis, Patient, Viral, Ageing, Genetically modified bacteria, Disease, Pharmaceutical industry, Palladium, Growth

The conjunctivitis treatment market is expected to register a CAGR of 4.1% over the forecast period.

Key Points: 
  • The conjunctivitis treatment market is expected to register a CAGR of 4.1% over the forecast period.
  • Thus the incidence of allergic conjunctivitis is expected to contribute to the market's growth during the forecast period.
  • The rising incidence of hemorrhagic conjunctivitis is expected to drive the demand for conjunctivitis treatment, thereby contributing to market growth.
  • The conjunctivitis treatment market is moderately consolidated in nature due to the presence of several companies operating globally as well as regionally.

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Monday, August 7, 2023
OAG, ASC, Clinical trial, Marketing, AMD, Trial of the century, Line of credit, Eye, SOFR, Month, Inflammation, Șaeș, Pain, Intraocular pressure, Interest, Ocular hypertension, Patient, Allergic conjunctivitis, Ophthalmology, Barings LLC, Growth, Webcast, OHT, Depreciation, Abdominal ultrasonography, Research, Axitinib, FDA, Summit, Treatment, Safety, Beauty salon, Pharmaceutical industry, Telescopic sight, Video game, Birth control, Arms industry

“The progress at Ocular Therapeutix over this last quarter has been significant,” said Antony Mattessich, President and CEO.

Key Points: 
  • “The progress at Ocular Therapeutix over this last quarter has been significant,” said Antony Mattessich, President and CEO.
  • The Company intends to initiate the first of two planned pivotal trials in wet AMD in Q3 2023.
  • Non-cash charges for stock-based compensation and depreciation and amortization were $5.1 million in the second quarter of 2023 versus $4.8 million for the comparable quarter in 2022.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.

Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform

Retrieved on: 
Tuesday, July 25, 2023
Health, Surgery, Other Science, General Health, Research, Science, Optical, DED, Ophthalmic, OTCQB, OSD, Biomarker, Lactoferrin, Telecanthus, MD, Patient, Allergic conjunctivitis, Diagnosis, Tear, Immunoglobulin E, Pharmaceutical industry, Medical imaging

T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management of patients suffering from ocular surface disease (OSD).

Key Points: 
  • T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management of patients suffering from ocular surface disease (OSD).
  • While today marks a milestone for the company with this initial shipment of its novel testing platform, it represents only the first phase that will focus on TOTAL IgE.
  • Rob Sambursky, MD, President of Verséa Ophthalmics stated: “Verséa Ophthalmics is proud to bring the innovative T-POC Quantitative Testing Platform to eye care professionals to aid them in appropriately diagnosing, managing, and treating their patients with ocular surface disease.
  • For more information on the T-POC Quantitative Testing Platform, please visit www.versea.com/ophthalmics .

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

Retrieved on: 
Tuesday, July 18, 2023
Surgery, Medical Supplies, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Optical, Oaktree Capital Management, Allergy, Cornea, Keratitis, Eye, Ophthalmology, VKC, Optometry, Vernal keratoconjunctivitis, EBITDA, Acquisition, Patient, Risk, Allergic conjunctivitis, Tobramycin, Conjunctivitis, Full, Pharmaceutical industry

NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.

Key Points: 
  • NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.
  • VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults and holds orphan-drug exclusivity.
  • ZERVIATE® (cetirizine ophthalmic solution) 0.24%, a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis.
  • VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children from four years of age through adolescence.

Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America

Retrieved on: 
Tuesday, July 18, 2023
General Health, Pharmaceutical, Optical, Health, Inflammation, Infection, Glaucoma, IOP, Keratitis, Medication, Harrow, Research, Vernal keratoconjunctivitis, Telecanthus, Ocular hypertension, Harrow Health, Patient, Allergic conjunctivitis, Conjunctivitis, Pharmaceutical industry, House of Santen

Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.

Key Points: 
  • Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.
  • Under the terms of the agreement, Santen grants Visiox exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI®.
  • Santen is eligible to receive sales milestone payments, as well as royalties on net U.S. sales of OMLONTI®.
  • Santen will receive an upfront payment for the asset transfer and the out-licensing and is eligible for royalties on net sales of Verkazia® and Cationorm® Plus.

Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide

Retrieved on: 
Wednesday, July 12, 2023
DED, Research, Telecanthus, CLIA, Patient, SAN, Ophthalmology, Allergic conjunctivitis, Diagnosis, Immunoglobulin E, Medical imaging, Pharmaceutical industry, Biotechnology

SAN DIEGO, CA, July 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire  – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has begun shipping revenue generating validation kits of one of its ophthalmological diagnostic assays. The proprietary assay is designed for the diagnosis of dry eye disease (DED) in patients at the point-of-care by measuring levels of Ocular Immunoglobulin E (IgE), a key biomarker primarily associated with non-specific, allergic conjunctivitis, which often mimics DED.

Key Points: 
  • ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has begun shipping revenue generating validation kits of one of its ophthalmological diagnostic assays.
  • Once initial validation testing is done, the Company anticipates clinics will begin monthly reordering of tests.
  • Additionally, AXIM’s partner Verseá Ophthalmics continues to meet with clinics regarding the diagnostic assay platform and continues acquiring additional commitments.
  • AXIM aims to address this discrepancy with its ocular diagnostic solution portfolio, beginning with the IgE assay.

AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide

Retrieved on: 
Wednesday, July 12, 2023
DED, Research, Telecanthus, CLIA, Patient, SAN, Ophthalmology, Allergic conjunctivitis, Diagnosis, Immunoglobulin E, Medical imaging, Pharmaceutical industry, Biotechnology

SAN DIEGO, CA, July 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire  – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has begun shipping revenue generating validation kits of one of its ophthalmological diagnostic assays. The proprietary assay is designed for the diagnosis of dry eye disease (DED) in patients at the point-of-care by measuring levels of Ocular Immunoglobulin E (IgE), a key biomarker primarily associated with non-specific, allergic conjunctivitis, which often mimics DED.

Key Points: 
  • ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has begun shipping revenue generating validation kits of one of its ophthalmological diagnostic assays.
  • Once initial validation testing is done, the Company anticipates clinics will begin monthly reordering of tests.
  • Additionally, AXIM’s partner Verseá Ophthalmics continues to meet with clinics regarding the diagnostic assay platform and continues acquiring additional commitments.
  • AXIM aims to address this discrepancy with its ocular diagnostic solution portfolio, beginning with the IgE assay.